Delineation of the Clotrimazole/TRAM-34 Binding Site on the Intermediate Conductance Calcium-activated Potassium Channel, IKCa1

Heike Wulff, George A. Gutman, Michael D. Cahalan, K. George Chandy

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Selective and potent triarylmethane blockers of the intermediate conductance calcium-activated potassium channel, IKCa1, have therapeutic use in sickle cell disease and secretory diarrhea and as immunosuppressants. Clotrimazole, a membrane-permeant triarylmethane, blocked IKCa1 with equal affinity when applied externally or internally, whereas a membrane-impermeant derivative TRAM-30 blocked the channel only when applied to the cytoplasmic side, indicating an internal drug-binding site. Introduction of the S5-P-S6 region of the triarylmethane-insensitive small conductance calcium-activated potassium channel SKCa3 into IKCa1 rendered the channel resistant to triarylmethanes. Replacement of Thr250 or Val275 in IKCa1 with the corresponding SKCa3 residues selectively abolished triarylmethane sensitivity without affecting the affinity of the channel for tetraethylammonium, charybdotoxin, and nifedipine. Introduction of these two residues into SKCa3 rendered the channel sensitive to triarylmethanes. In a molecular model of IKCa1, Thr250 and Val275 line a water-filled cavity just below the selectivity filter. Structure-activity studies suggest that the side chain methyl groups of Thr250 and Val275 may lock the triarylmethanes in place via hydrophobic interactions with the π-electron clouds of the phenyl rings. The heterocyclic moiety may project into the selectivity filter and obstruct the ion-conducting pathway from the inside.

Original languageEnglish (US)
Pages (from-to)32040-32045
Number of pages6
JournalJournal of Biological Chemistry
Volume276
Issue number34
DOIs
StatePublished - Aug 24 2001

Fingerprint

Intermediate-Conductance Calcium-Activated Potassium Channels
Clotrimazole
Small-Conductance Calcium-Activated Potassium Channels
Binding Sites
Charybdotoxin
Membranes
S 6
Molecular Models
Tetraethylammonium
Sickle Cell Anemia
Therapeutic Uses
Nifedipine
Immunosuppressive Agents
Hydrophobic and Hydrophilic Interactions
Diarrhea
Electrons
Ions
Derivatives
Water
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry

Cite this

Delineation of the Clotrimazole/TRAM-34 Binding Site on the Intermediate Conductance Calcium-activated Potassium Channel, IKCa1. / Wulff, Heike; Gutman, George A.; Cahalan, Michael D.; Chandy, K. George.

In: Journal of Biological Chemistry, Vol. 276, No. 34, 24.08.2001, p. 32040-32045.

Research output: Contribution to journalArticle

Wulff, Heike ; Gutman, George A. ; Cahalan, Michael D. ; Chandy, K. George. / Delineation of the Clotrimazole/TRAM-34 Binding Site on the Intermediate Conductance Calcium-activated Potassium Channel, IKCa1. In: Journal of Biological Chemistry. 2001 ; Vol. 276, No. 34. pp. 32040-32045.
@article{37a2369adc3c49babcb230b599dedcc6,
title = "Delineation of the Clotrimazole/TRAM-34 Binding Site on the Intermediate Conductance Calcium-activated Potassium Channel, IKCa1",
abstract = "Selective and potent triarylmethane blockers of the intermediate conductance calcium-activated potassium channel, IKCa1, have therapeutic use in sickle cell disease and secretory diarrhea and as immunosuppressants. Clotrimazole, a membrane-permeant triarylmethane, blocked IKCa1 with equal affinity when applied externally or internally, whereas a membrane-impermeant derivative TRAM-30 blocked the channel only when applied to the cytoplasmic side, indicating an internal drug-binding site. Introduction of the S5-P-S6 region of the triarylmethane-insensitive small conductance calcium-activated potassium channel SKCa3 into IKCa1 rendered the channel resistant to triarylmethanes. Replacement of Thr250 or Val275 in IKCa1 with the corresponding SKCa3 residues selectively abolished triarylmethane sensitivity without affecting the affinity of the channel for tetraethylammonium, charybdotoxin, and nifedipine. Introduction of these two residues into SKCa3 rendered the channel sensitive to triarylmethanes. In a molecular model of IKCa1, Thr250 and Val275 line a water-filled cavity just below the selectivity filter. Structure-activity studies suggest that the side chain methyl groups of Thr250 and Val275 may lock the triarylmethanes in place via hydrophobic interactions with the π-electron clouds of the phenyl rings. The heterocyclic moiety may project into the selectivity filter and obstruct the ion-conducting pathway from the inside.",
author = "Heike Wulff and Gutman, {George A.} and Cahalan, {Michael D.} and Chandy, {K. George}",
year = "2001",
month = "8",
day = "24",
doi = "10.1074/jbc.M105231200",
language = "English (US)",
volume = "276",
pages = "32040--32045",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "34",

}

TY - JOUR

T1 - Delineation of the Clotrimazole/TRAM-34 Binding Site on the Intermediate Conductance Calcium-activated Potassium Channel, IKCa1

AU - Wulff, Heike

AU - Gutman, George A.

AU - Cahalan, Michael D.

AU - Chandy, K. George

PY - 2001/8/24

Y1 - 2001/8/24

N2 - Selective and potent triarylmethane blockers of the intermediate conductance calcium-activated potassium channel, IKCa1, have therapeutic use in sickle cell disease and secretory diarrhea and as immunosuppressants. Clotrimazole, a membrane-permeant triarylmethane, blocked IKCa1 with equal affinity when applied externally or internally, whereas a membrane-impermeant derivative TRAM-30 blocked the channel only when applied to the cytoplasmic side, indicating an internal drug-binding site. Introduction of the S5-P-S6 region of the triarylmethane-insensitive small conductance calcium-activated potassium channel SKCa3 into IKCa1 rendered the channel resistant to triarylmethanes. Replacement of Thr250 or Val275 in IKCa1 with the corresponding SKCa3 residues selectively abolished triarylmethane sensitivity without affecting the affinity of the channel for tetraethylammonium, charybdotoxin, and nifedipine. Introduction of these two residues into SKCa3 rendered the channel sensitive to triarylmethanes. In a molecular model of IKCa1, Thr250 and Val275 line a water-filled cavity just below the selectivity filter. Structure-activity studies suggest that the side chain methyl groups of Thr250 and Val275 may lock the triarylmethanes in place via hydrophobic interactions with the π-electron clouds of the phenyl rings. The heterocyclic moiety may project into the selectivity filter and obstruct the ion-conducting pathway from the inside.

AB - Selective and potent triarylmethane blockers of the intermediate conductance calcium-activated potassium channel, IKCa1, have therapeutic use in sickle cell disease and secretory diarrhea and as immunosuppressants. Clotrimazole, a membrane-permeant triarylmethane, blocked IKCa1 with equal affinity when applied externally or internally, whereas a membrane-impermeant derivative TRAM-30 blocked the channel only when applied to the cytoplasmic side, indicating an internal drug-binding site. Introduction of the S5-P-S6 region of the triarylmethane-insensitive small conductance calcium-activated potassium channel SKCa3 into IKCa1 rendered the channel resistant to triarylmethanes. Replacement of Thr250 or Val275 in IKCa1 with the corresponding SKCa3 residues selectively abolished triarylmethane sensitivity without affecting the affinity of the channel for tetraethylammonium, charybdotoxin, and nifedipine. Introduction of these two residues into SKCa3 rendered the channel sensitive to triarylmethanes. In a molecular model of IKCa1, Thr250 and Val275 line a water-filled cavity just below the selectivity filter. Structure-activity studies suggest that the side chain methyl groups of Thr250 and Val275 may lock the triarylmethanes in place via hydrophobic interactions with the π-electron clouds of the phenyl rings. The heterocyclic moiety may project into the selectivity filter and obstruct the ion-conducting pathway from the inside.

UR - http://www.scopus.com/inward/record.url?scp=0035943601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035943601&partnerID=8YFLogxK

U2 - 10.1074/jbc.M105231200

DO - 10.1074/jbc.M105231200

M3 - Article

C2 - 11425865

AN - SCOPUS:0035943601

VL - 276

SP - 32040

EP - 32045

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 34

ER -